Solid Biosciences Inc at Needham Healthcare Conference (Virtual) Transcript
Good morning, everyone, and thank you for joining me at the fourth day of the Annual Needham & Company Healthcare Conference. My name is Gil Blum, and I am a senior biotech analyst here at Needham & Company, covering the gene therapy and immuno-oncology subsectors.
It is my pleasure to have with me today, Bo Cumbo, the CEO of Solid Biotech (sic - see slide 1, "Solid Biosciences"). (Conference Instructions) And with that, Bo, please go ahead.
First, thank you, Needham & Company. And thank you, Gil, for the invitation. Really do appreciate the opportunity to present. I'm going to make a number of forward-looking statements today. These forward-looking statements involve risks and uncertainties, many of which are beyond Solid's control. Actual results could materially differ from these forward-looking statements. Please take a moment to review these statements prior to investing.
With that said, this year, 2023, is a year of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
